Sarepta Therapeutics, Inc. (0L35.L)
USD 53.05
(-7.49%)
USD 53.05
(-7.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.4 Billion USD | -12.33% |
| 2022 | 2.74 Billion USD | 23.58% |
| 2021 | 2.21 Billion USD | -0.13% |
| 2020 | 2.22 Billion USD | 121.27% |
| 2019 | 1 Billion USD | 64.75% |
| 2018 | 609.79 Million USD | 17.55% |
| 2017 | 518.74 Million USD | 493.44% |
| 2016 | 87.41 Million USD | 4.77% |
| 2015 | 83.43 Million USD | 76.1% |
| 2014 | 47.38 Million USD | 6.77% |
| 2013 | 44.37 Million USD | -45.43% |
| 2012 | 81.31 Million USD | 248.22% |
| 2011 | 23.35 Million USD | -52.14% |
| 2010 | 48.79 Million USD | 34.06% |
| 2009 | 36.39 Million USD | 271.25% |
| 2008 | 9.8 Million USD | -20.01% |
| 2007 | 12.25 Million USD | 288.98% |
| 2006 | 3.15 Million USD | 14.66% |
| 2005 | 2.74 Million USD | 22.15% |
| 2004 | 2.24 Million USD | -40.03% |
| 2003 | 3.75 Million USD | -26.77% |
| 2002 | 5.12 Million USD | 56.11% |
| 2001 | 3.28 Million USD | 90.45% |
| 2000 | 1.72 Million USD | 72.28% |
| 1999 | 1 Million USD | -16.67% |
| 1998 | 1.2 Million USD | 140.0% |
| 1997 | 500 Thousand USD | -85.29% |
| 1996 | 3.4 Million USD | 1033.33% |
| 1995 | 300 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.26 Billion USD | -5.91% |
| 2024 Q2 | 2.34 Billion USD | 3.71% |
| 2023 Q1 | 2.34 Billion USD | -14.45% |
| 2023 FY | 2.4 Billion USD | -12.33% |
| 2023 Q4 | 2.4 Billion USD | 2.55% |
| 2023 Q3 | 2.34 Billion USD | -1.64% |
| 2023 Q2 | 2.38 Billion USD | 1.6% |
| 2022 Q2 | 2.27 Billion USD | 3.23% |
| 2022 Q3 | 2.72 Billion USD | 20.04% |
| 2022 Q4 | 2.74 Billion USD | 0.66% |
| 2022 FY | 2.74 Billion USD | 23.58% |
| 2022 Q1 | 2.19 Billion USD | -0.93% |
| 2021 Q4 | 2.21 Billion USD | 1.24% |
| 2021 Q1 | 2.22 Billion USD | 0.31% |
| 2021 Q2 | 2.27 Billion USD | 1.98% |
| 2021 Q3 | 2.19 Billion USD | -3.57% |
| 2021 FY | 2.21 Billion USD | -0.13% |
| 2020 Q3 | 1.88 Billion USD | 2.63% |
| 2020 FY | 2.22 Billion USD | 121.27% |
| 2020 Q2 | 1.84 Billion USD | 2.09% |
| 2020 Q4 | 2.22 Billion USD | 17.7% |
| 2020 Q1 | 1.8 Billion USD | 79.42% |
| 2019 FY | 1 Billion USD | 64.75% |
| 2019 Q2 | 648.58 Million USD | 5.4% |
| 2019 Q3 | 707.26 Million USD | 9.05% |
| 2019 Q4 | 1 Billion USD | 42.04% |
| 2019 Q1 | 615.33 Million USD | 0.91% |
| 2018 FY | 609.79 Million USD | 17.55% |
| 2018 Q2 | 548.11 Million USD | 4.7% |
| 2018 Q1 | 523.52 Million USD | 0.92% |
| 2018 Q3 | 543.05 Million USD | -0.92% |
| 2018 Q4 | 609.79 Million USD | 12.29% |
| 2017 Q2 | 72.36 Million USD | -12.17% |
| 2017 Q1 | 82.39 Million USD | -5.75% |
| 2017 FY | 518.74 Million USD | 493.44% |
| 2017 Q4 | 518.74 Million USD | 403.03% |
| 2017 Q3 | 103.12 Million USD | 42.5% |
| 2016 Q1 | 74.4 Million USD | -10.83% |
| 2016 Q2 | 82.6 Million USD | 11.03% |
| 2016 Q3 | 78.68 Million USD | -4.75% |
| 2016 FY | 87.41 Million USD | 4.77% |
| 2016 Q4 | 87.41 Million USD | 11.09% |
| 2015 FY | 83.43 Million USD | 76.1% |
| 2015 Q3 | 61.51 Million USD | -7.26% |
| 2015 Q2 | 66.33 Million USD | 58.13% |
| 2015 Q1 | 41.94 Million USD | -11.46% |
| 2015 Q4 | 83.43 Million USD | 35.63% |
| 2014 FY | 47.38 Million USD | 6.77% |
| 2014 Q2 | 37.38 Million USD | -19.47% |
| 2014 Q3 | 32.85 Million USD | -12.13% |
| 2014 Q4 | 47.38 Million USD | 44.21% |
| 2014 Q1 | 46.42 Million USD | 4.62% |
| 2013 FY | 44.37 Million USD | -45.43% |
| 2013 Q3 | 57.49 Million USD | -39.36% |
| 2013 Q2 | 94.81 Million USD | -10.6% |
| 2013 Q1 | 106.05 Million USD | 30.43% |
| 2013 Q4 | 44.37 Million USD | -22.82% |
| 2012 Q4 | 81.31 Million USD | 41.05% |
| 2012 Q3 | 57.64 Million USD | 194.11% |
| 2012 Q2 | 19.6 Million USD | -39.92% |
| 2012 Q1 | 32.62 Million USD | 39.72% |
| 2012 FY | 81.31 Million USD | 248.22% |
| 2011 Q1 | 46.11 Million USD | -5.5% |
| 2011 Q2 | 39.78 Million USD | -13.72% |
| 2011 Q3 | 29.33 Million USD | -26.27% |
| 2011 Q4 | 23.35 Million USD | -20.39% |
| 2011 FY | 23.35 Million USD | -52.14% |
| 2010 Q1 | 29.35 Million USD | -19.36% |
| 2010 FY | 48.79 Million USD | 34.06% |
| 2010 Q3 | 46.69 Million USD | 16.09% |
| 2010 Q4 | 48.79 Million USD | 4.49% |
| 2010 Q2 | 40.22 Million USD | 37.05% |
| 2009 Q3 | 45.61 Million USD | 58.24% |
| 2009 Q4 | 36.39 Million USD | -20.22% |
| 2009 Q2 | 28.82 Million USD | 104.07% |
| 2009 Q1 | 14.12 Million USD | 44.09% |
| 2009 FY | 36.39 Million USD | 271.25% |
| 2008 Q2 | 11.33 Million USD | -22.86% |
| 2008 Q1 | 14.69 Million USD | 19.89% |
| 2008 Q4 | 9.8 Million USD | -25.59% |
| 2008 Q3 | 13.17 Million USD | 16.24% |
| 2008 FY | 9.8 Million USD | -20.01% |
| 2007 Q2 | 6.99 Million USD | 60.89% |
| 2007 Q4 | 12.25 Million USD | 5.3% |
| 2007 FY | 12.25 Million USD | 288.98% |
| 2007 Q1 | 4.34 Million USD | 37.96% |
| 2007 Q3 | 11.63 Million USD | 66.43% |
| 2006 Q4 | 3.15 Million USD | 44.34% |
| 2006 Q3 | 2.18 Million USD | -3.62% |
| 2006 Q1 | 2.2 Million USD | -19.58% |
| 2006 FY | 3.15 Million USD | 14.66% |
| 2006 Q2 | 2.26 Million USD | 2.49% |
| 2005 Q3 | 2.52 Million USD | 30.93% |
| 2005 Q1 | 2.27 Million USD | 1.26% |
| 2005 Q4 | 2.74 Million USD | 8.93% |
| 2005 FY | 2.74 Million USD | 22.15% |
| 2005 Q2 | 1.92 Million USD | -15.42% |
| 2004 Q4 | 2.24 Million USD | 66.71% |
| 2004 FY | 2.24 Million USD | -40.03% |
| 2004 Q2 | 2.16 Million USD | -21.21% |
| 2004 Q3 | 1.34 Million USD | -37.73% |
| 2004 Q1 | 2.75 Million USD | -26.68% |
| 2003 FY | 3.75 Million USD | -26.77% |
| 2003 Q4 | 3.75 Million USD | 62.46% |
| 2003 Q3 | 2.3 Million USD | 78.12% |
| 2003 Q2 | 1.29 Million USD | -19.98% |
| 2003 Q1 | 1.61 Million USD | -68.37% |
| 2002 Q2 | 3.95 Million USD | -16.2% |
| 2002 FY | 5.12 Million USD | 56.11% |
| 2002 Q1 | 4.71 Million USD | 43.85% |
| 2002 Q3 | 4.91 Million USD | 24.28% |
| 2002 Q4 | 5.12 Million USD | 4.2% |
| 2001 Q4 | 3.28 Million USD | 107.45% |
| 2001 Q1 | 1.61 Million USD | -6.09% |
| 2001 Q3 | 1.58 Million USD | -2.02% |
| 2001 Q2 | 1.61 Million USD | -0.23% |
| 2001 FY | 3.28 Million USD | 90.45% |
| 2000 Q1 | 766.97 Thousand USD | -23.3% |
| 2000 Q3 | 1.31 Million USD | 19.17% |
| 2000 Q2 | 1.1 Million USD | 44.02% |
| 2000 FY | 1.72 Million USD | 72.28% |
| 2000 Q4 | 1.72 Million USD | 30.88% |
| 1999 FY | 1 Million USD | -16.67% |
| 1999 Q1 | 700 Thousand USD | -41.67% |
| 1999 Q4 | 1 Million USD | 42.86% |
| 1999 Q2 | 400 Thousand USD | -42.86% |
| 1999 Q3 | 700 Thousand USD | 75.0% |
| 1998 Q2 | 400 Thousand USD | -20.0% |
| 1998 Q3 | 1.2 Million USD | 200.0% |
| 1998 FY | 1.2 Million USD | 140.0% |
| 1998 Q1 | 500 Thousand USD | 0.0% |
| 1998 Q4 | 1.2 Million USD | 0.0% |
| 1997 Q3 | 800 Thousand USD | -11.11% |
| 1997 Q2 | 900 Thousand USD | -74.29% |
| 1997 FY | 500 Thousand USD | -85.29% |
| 1997 Q1 | 3.5 Million USD | 1066.67% |
| 1997 Q4 | 500 Thousand USD | -37.5% |
| 1996 FY | 3.4 Million USD | 1033.33% |
| 1996 Q4 | 300 Thousand USD | 0.0% |
| 1995 FY | 300 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -285.443% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1807.421% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -289.382% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -808.546% |
| bluebird bio, Inc. | 424.62 Million USD | -466.44% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -3398.072% |
| Imunon, Inc. | 8.53 Million USD | -28095.998% |
| Editas Medicine, Inc. | 150.05 Million USD | -1502.894% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 88.306% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 31.387% |
| Myriad Genetics, Inc. | 312.9 Million USD | -668.693% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -135.947% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -393.422% |
| Verastem, Inc. | 71.18 Million USD | -3278.857% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 96.507% |
| Waters Corporation | 3.47 Billion USD | 30.815% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 95.364% |
| Biogen Inc. | 12.04 Billion USD | 80.032% |
| Nektar Therapeutics | 267.04 Million USD | -800.683% |
| Perrigo Company plc | 6.04 Billion USD | 60.186% |
| Dynavax Technologies Corporation | 375.02 Million USD | -541.356% |
| Illumina, Inc. | 4.36 Billion USD | 44.91% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -6737.511% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1128.805% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -837.792% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -6349.745% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -27.258% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -2817.811% |
| Evolus, Inc. | 209.68 Million USD | -1047.062% |
| Adicet Bio, Inc. | 37.12 Million USD | -6379.631% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -5879.314% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 66.157% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -263.994% |
| FibroGen, Inc. | 585.72 Million USD | -310.641% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 51.093% |
| OPKO Health, Inc. | 622.47 Million USD | -286.397% |
| Homology Medicines, Inc. | 118.53 Million USD | -1929.172% |
| Geron Corporation | 146.12 Million USD | -1545.992% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 40.619% |
| Exelixis, Inc. | 678.44 Million USD | -254.522% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -11883.653% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -19089.716% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -858.996% |
| Zoetis Inc. | 9.29 Billion USD | 74.123% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -505.459% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -4791.083% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 53.295% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -4864.886% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 7.611% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1994.937% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -45.82% |
| Blueprint Medicines Corporation | 918.64 Million USD | -161.826% |
| Insmed Incorporated | 1.66 Billion USD | -44.74% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1322.503% |
| Incyte Corporation | 1.59 Billion USD | -51.057% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -102.871% |